logo.png
Orphazyme reports business highlights and financial results in Interim Report First Half 2021
August 31, 2021 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 21/2021CVR No.: 32266355 Copenhagen, Denmark, August 31, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company, today...
logo.png
Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021
August 25, 2021 08:33 ET | ORPHAZYME A/S
Orphazyme A/SInvestor news        No. 08/2021Company Registration No. 32266355 Copenhagen – August 25, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces...
logo.png
Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherited Metabolic Disease
August 23, 2021 05:04 ET | ORPHAZYME A/S
Orphazyme A/SInvestor newsNo. 07/2021Company Registration No. 32266355 Arimoclomol was well-tolerated with a statistically significant and clinically meaningful effect on disease progression ...
logo.png
New publication date for Orphazyme’s Interim Report H1 2021
August 05, 2021 12:11 ET | ORPHAZYME A/S
Orphazyme A/SInvestor news        No. 06/2021Company Registration No. 32266355 Copenhagen – August 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced...
logo.png
Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research
June 28, 2021 02:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 21/2021Company Registration No. 32266355 Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today...
logo.png
Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC
June 28, 2021 00:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 20/2021Inside informationCompany Registration No. 32266355 -Significant headcount reduction of global workforce to free resources- -Changes to the...
logo.png
Major shareholder announcement
June 24, 2021 07:31 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 19/2021Company Registration No. 32266355 Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
logo.png
Major shareholder announcement
June 23, 2021 05:43 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 18/2021Company Registration No. 32266355 Copenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
logo.png
Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C
June 18, 2021 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 16/2021Inside informationCompany Registration No. 32266355   Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage...
logo.png
Major shareholder announcement
June 15, 2021 11:05 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 16/2021Company Registration No. 32266355 Copenhagen, Denmark, June 15, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...